| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Pathways |
Authors' Affiliation: Departments of Surgical Oncology and Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Mien-Chie Hung, Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3668; Fax: 713-794-0209; E-mail: mhung{at}manderson.org.
Human epidermal growth factor receptor (HER)-2 is a member of the HER tyrosine kinase family, which regulates cell growth and proliferation. HER-2 is overexpressed in 20% to 30% of breast cancers and has been associated with an aggressive phenotype and a poorer prognosis, making it an appealing therapeutic target. Since 1998, the anti-HER-2 antibody trastuzumab has been used for the treatment of women with HER-2-positive metastatic breast cancer. Results from large trials have established a role for trastuzumab in the adjuvant setting for the treatment of high-risk primary breast cancer as well. Tyrosine kinase inhibitors that target HER-2 are also very promising therapies and are likely to be incorporated into clinical practice in the near future. HER-2-targeted therapies represent a major step forward in achieving our goal of delivering individualized targeted therapy for breast cancer. However, there are many unanswered questions about the optimal use of these agents. Ongoing research will better elucidate the best combination therapies to overcome resistance to HER-2-targeted agents and will help identify patients at high enough risk to warrant their toxicity.
This article has been cited by other articles:
|
|
 |
|
  A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties J. Immunol., July 1, 2008; 181(1): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules J. Nucl. Med., May 1, 2008; 49(5): 804 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Chinni, H. Yamamoto, Z. Dong, A. Sabbota, R. D. Bonfil, and M. L. Cher CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone Mol. Cancer Res., March 1, 2008; 6(3): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hasegawa, C. Hu, T. Nakamura, J. D. Marks, S. J. Russell, and K.-W. Peng Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins J. Virol., December 1, 2007; 81(23): 13149 - 13157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response Ann. Surg. Oncol., July 1, 2007; 14(7): 2150 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-T. Chiang, T.-D. Way, and J.-K. Lin Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin Mol. Cancer Ther., July 1, 2007; 6(7): 2127 - 2138. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
